Bernstein Says Sell SMMT: Why Summit Therapeutics Stock Could Drop More
Bernstein remains bearish on Summit, citing doubts about trial success and expecting weak results ahead.
/ 5 items
#SMMT↓
Wall Street Turns Cautious on Summit Therapeutics: Bernstein Slaps Underperform Rating, Predicts Phase 3 Failures
Analysts warn Summit may fail key trials, lacks revenue, and faces pressure—raising doubts about its future and stock upside.
Summit Therapeutics Drops 21%: The “Continue” News That Spooked Investors
Summit stock fell after its cancer drug update was just “keep going,” not the big win investors hoped for.
Stifel Sees 134% Upside in Summit Therapeutics as Ivonescimab Eyes $200B Market
Stifel rates Summit Therapeutics a Buy. Its new cancer drug looks promising, and strong trial results could send the stock much higher.
Summit's Lung Cancer Drug: A Tale of Two Continents
Summit Therapeutics' promising lung cancer drug, ivonescimab, shows great results in China but struggles in Western trials, raising questions about its global future and impact on biotech.